Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ENSG00000256199 is annotated as a "novel transcript, antisense to RASSF3" and classified as a non-coding natural antisense RNA (NAT). Antisense transcripts are a common genomic feature in eukaryotes, frequently overlapping with protein-coding genes on the opposite DNA strand[2][3]. These RNAs regulate gene expression by mechanisms such as RNA masking, transcriptional interference, or RNA interference, often leading to alterations in the stability, splicing, or translation of the sense (protein-coding) transcript[2][3]. There is no evidence that ENSG00000256199 encodes a protein or functions as a receptor, enzyme, or druggable molecular target. Instead, its primary role is likely to influence the expression of the adjacent RASSF3 tumor suppressor gene. While antisense RNAs can have significant biological roles and may be therapeutically relevant in the future, this specific antisense transcript is not currently considered a direct target for existing drugs or therapies[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RASSF3 (ENSG00000256199).